---
title: "Baseline intratumoral TCRβ and TCRγ repertoires predict ICI response in advanced renal cell carcin"
id: "medrxiv-1-baseline-intratumoral-tcrbeta-and-tcrgamma-repertoires-predict-response-to"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-1-baseline-intratumoral-tcrbeta-and-tcrgamma-repertoires-predict-response-to"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.01.26361892v1?rss=1"
published_at: "2026-09-06T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Baseline intratumoral TCRβ and TCRγ repertoires predict ICI response in advanced renal cell carcin
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-1-baseline-intratumoral-tcrbeta-and-tcrgamma-repertoires-predict-response-to
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.01.26361892v1?rss=1)
- **Published At:** 2026-09-06T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Immune checkpoint inhibitors (ICIs) benefit only a subset of patients with advanced renal cell carcinoma (**RCC**); the study evaluated baseline intratumoral T-cell receptor repertoires as predictive biomarkers. - This real-world cohort predominantly received first-line **ICI**-based regimens and underwent paired characterization of baseline intratumoral **TCRβ** and **TCRγ** repertoires. - Responders displayed a significantly more even **TCRβ** repertoire, and increased **TCRγ** diversity and clonal richness; non-responders showed greater **TCRγ** clonal dominance. - Preferential usage of specific TRBV genes (including **TRBV5.7**, **TRBV7.1**, and **TRBV18**) correlated with clinical response and longer progression-free survival. - A combined model integrating the most informative **TCRβ** and **TCRγ** variables (random forest) achieved an AUC of 0.90 in leave-one-out cross-validation, with 100% sensitivity and 81.8% specificity at the chosen threshold. - Authors state this is the first study to simultaneously profile baseline intratumoral **TCRβ** and **TCRγ** repertoires in advanced RCC patients predominantly treated with first-line immune checkpoint blockade. - Findings support baseline intratumoral **TCR** repertoire features as candidate tissue biomarkers for pretreatment patient stratification and motivate prospective validation studies. - The report is a medRxiv preprint (not peer reviewed); datasets are available from corresponding authors upon reasonable request. - Ethical approvals were obtained from Clinical Research Ethics Committee of Galicia (CEIm-G; 2022/429) and Clinical Research Ethics Committee of Hospital 12 de Octubre (18/055). - Funding sources include Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades, and Axencia Galega de Innovacion.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=lUPbXXYZsanuf9yJ8u.vBjSNbydLR7PHA53qerzuu_A-1788697943.1013243-1.2.1.1-LLO6EX4zgQ6dZXHrR.ryVIwQgXeF3FVsy5hWU1eHaRQjqc0VIbIYgSN716.UHO2Q) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.01.26361892v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Baseline intratumoral TCRbeta; and TCRgamma; repertoires predict response to immune checkpoint inhibitors in advanced renal cell carcinoma [ View ORCID Profile](http://orcid.org/0009-0006-0385-1021)Manuel Pino Gonzalez, Martin Emilio Lazaro Quintela, Guillermo de Velasco Oria de Rueda, Marta Duenas Porto, Irene Alonso Alvarez, Alejandro Francisco Fernandez, Maria Pilar San Miguel Fraile, Jose Antonio Ortiz Rey, Maria Gallardo Gomez, Laura Carracedo Videira, Sandra Gallach Garcia, Eloisa Jantus Lewintre, Monica Martinez Fernandez doi: https://doi.org/10.64898/2026.09.01.26361892 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Manuel Pino Gonzalez 1 Translational Oncology Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Hospital Alvaro Cunqueiro, Carretera Clara Campoamor, 341, 36213 (Vigo), Spain.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Manuel%2BPino%2BGonzalez%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Pino%20Gonzalez%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AManuel%2BPino%2BGonzalez%2B) * [ORCID record for Manuel Pino Gonzalez](http://orcid.org/0009-0006-0385-1021 "Open in new tab") Martin Emilio Lazaro Quintela 1 Translational Oncology Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Hospital Alvaro Cunqueiro, Carretera Clara Campoamor, 341, 36213 (Vigo), Spain.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Martin%2BEmilio%2BLazaro%2BQuintela%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lazaro%20Quintela%20ME&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMartin%2BEmilio%2BLazaro%2BQuintela%2B) Guillermo de Velasco Oria de Rueda 2 Department of Medical Oncology, Biomedical Research Institute I+12, Hospital Universitario "12 de Octubre", 28041 (Madrid), Spain.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Guillermo%2Bde%2BVelasco%2BOria%2Bde%2BRueda%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Oria%20de%20Rueda%20GD&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AGuillermo%2Bde%2BVelasco%2BOria%2Bde%2BRueda%2B) Marta Duenas Porto 3 Molecular and Traslational Oncology Division, Biomedical Innovation Unit, CIEMAT. Cellular and Molecular Oncology and Genitourinary Tumor Group, Biomedical Research Institute Imas12, Hospital Universitario "12 de Octubre", (Madrid), Spain.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Marta%2BDuenas%2BPorto%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Duenas%20Porto%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMarta%2BDuenas%2BPorto%2B) Irene Alonso Alvarez 1 Translational Oncology Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Hospital Alvaro Cunqueiro, Carretera Clara Campoamor, 341, 36213 (Vigo), Spain.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Irene%2BAlonso%2BAlvarez%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Alonso%20Alvarez%20I&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AIrene%2BAlonso%2BAlvarez%2B) Alejandro Francisco Fernandez 1 Translational Oncology Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Hospital Alvaro Cunqueiro, Carretera Clara Campoamor, 341, 36213 (Vigo), Spain.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Alejandro%2BFrancisco%2BFernandez%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Francisco%20Fernandez%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAlejandro%2BFrancisco%2BFernandez%2B) Maria Pilar San Miguel Fraile 4 Department of Pathology. Uropathology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Hospital Alvaro Cunqueiro, Carretera Clara Campoamor, 341, 36213 (Vigo), Spain; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Maria%2BPilar%2BSan%2BMiguel%2BFraile%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=San%20Miguel%20Fraile%20MP&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMaria%2BPilar%2BSan%2BMiguel%2BFraile%2B) Jose Antonio Ortiz Rey 5 Department of Pathology. Uropathology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Hospital Alvaro Cunqueiro, Carretera Clara Campoamor, 341, 36213 (Vigo), Spain.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jose%2BAntonio%2BOrtiz%2BRey%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ortiz%20Rey%20JA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJose%2BAntonio%2BOrtiz%2BRey%2B) Maria Gallardo Gomez 1 Translational Oncology Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Hospital Alvaro Cunqueiro, Carretera Clara Campoamor, 341, 36213 (Vigo), Spain.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Maria%2BGallardo%2BGomez%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Gallardo%20Gomez%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMaria%2BGallardo%2BGomez%2B) Laura Carracedo Videira 1 Translational Oncology Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Hospital Alvaro Cunqueiro, Carretera Clara Campoamor, 341, 36213 (Vigo), Spain.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Laura%2BCarracedo%2BVideira%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Carracedo%20Videira%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALaura%2BCarracedo%2BVideira%2B) Sandra Gallach Garcia 6 Molecular Oncology Laboratory, General University Hospital of Valencia Research Foundation, 46014 (Valencia), Spain.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sandra%2BGallach%2BGarcia%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Gallach%20Garcia%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASandra%2BGallach%2BGarcia%2B) Eloisa Jantus Lewintre 7 IDM y Unidad Mixta UPV-CIPF de Investigacion en Mecanismos de Enfermedades y Nanomedicina, Centro de Investigacion Principe Felipe, Universitat Politecnica de Valencia, 46022 (Valencia), Spain. * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Eloisa%2BJantus%2BLewintre%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Jantus%20Lewintre%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEloisa%2BJantus%2BLewintre%2B) Monica Martinez Fernandez 1 Translational Oncology Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Hospital Alvaro Cunqueiro, Carretera Clara Campoamor, 341, 36213 (Vigo), Spain.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Monica%2BMartinez%2BFernandez%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Martinez%20Fernandez%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMonica%2BMartinez%2BFernandez%2B) * For correspondence: monica.martinez@iisgaliciasur.es * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.01.26361892v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1293840/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.01.26361892v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1293840/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.01.26361892v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1293840/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.09.01.26361892v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1293840/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.01.26361892v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1293840/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.01.26361892v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1293840/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of advanced renal cell carcinoma (RCC), yet only a subset of patients derives durable clinical benefit and no robust predictive biomarkers have been implemented in routine clinical practice. As T-cell receptor (TCR)-mediated antigen recognition underlies effective antitumor immunity, characterization of the intratumoral TCR repertoire may provide clinically relevant information for patient stratification. Here, we evaluated the predictive value of the baseline intratumoral TCRβ and TCRγ repertoires in a real-world cohort of patients with advanced RCC treated predominantly with first-line immune checkpoint inhibitor-based regimens. Responders exhibited a significantly more even TCRβ repertoire together with increased TCRγ diversity and clonal richness, whereas non-responders showed greater TCRγ clonal dominance. In addition, the preferential usage of specific TRBV genes, including TRBV5.7, TRBV7.1, and TRBV18, was associated with clinical response and longer progression-free survival. In this exploratory cohort, integration of the most informative TCRβ and TCRγ variables into a combined random forest model yielded an area under the receiver operating characteristic curve of 0.90 in leave-one-out cross-validation, with 100% sensitivity and 81.8% specificity at the selected threshold. To our knowledge, this is the first study to simultaneously characterize baseline intratumoral TCRβ and TCRγ repertoires in patients with advanced RCC predominantly receiving first-line immune checkpoint blockade. These findings support baseline intratumoral TCR repertoire features as candidate tissue biomarkers for pretreatment patient stratification and provide a rationale for the prospective validation of TCR repertoire profiling as a predictor of immunotherapy benefit in RCC. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Clinical Research Ethics Committee of Galicia (CEIm-G; 2022/429) gave ethical approval for this work. Clinical Research Ethics Committee of Hospital 12 de Octubre (18/055) gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The datasets supporting the findings of this study are available from the corresponding authors upon reasonable request. ## Funder Information Declared Instituto de Salud Carlos III, PI21/00348, CP20/00188 Ministerio de Ciencia, Innovación y Universidades, FPU23/00744 Axencia Galega de Innovacion, https://ror.org/02vcxyt85, IN606B-2024/014 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.01.26361892v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.04.10.26347909v2 "Pneumonia Detection in Paediatric Chest X-Rays using Ensembled Large Language Models")[Next ](https://www.medrxiv.org/content/10.64898/2026.09.01.26361911v1 "Socioeconomic inequalities in cannabis use among European adolescents: the role of access and risk perception") Posted September 06, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.01.26361892v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/04/2026.09.01.26361892.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.01.26361892v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.09.01.26361892v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/04/2026.09.01.26361892.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Baseline intratumoral TCRbeta; and TCRgamma; repertoires predict response to immune checkpoint inhibitors in advanced renal cell carcinoma Manuel Pino Gonzalez, Martin Emilio Lazaro Quintela, Guillermo de Velasco Oria de Rueda, Marta Duenas Porto, Irene Alonso Alvarez, Alejandro Francisco Fernandez, Maria Pilar San Miguel Fraile, Jose Antonio Ortiz Rey, Maria Gallardo Gomez, Laura Carracedo Videira, Sandra Gallach Garcia, Eloisa Jantus Lewintre, Monica Martinez Fernandez medRxiv 2026.09.01.26361892; doi: https://doi.org/10.64898/2026.09.01.26361892 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.01.26361892v1%26text%3DBaseline%2520intratumoral%2520TCRbeta%253B%2520and%2520TCRgamma%253B%2520repertoires%2520predict%2520response%2520to%2520immune%2520checkpoint%2520inhibitors%2520in%2520advanced%2520renal%2520cell%2520carcinoma "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.01.26361892v1%26t%3DBaseline%2520intratumoral%2520TCRbeta%253B%2520and%2520TCRgamma%253B%2520repertoires%2520predict%2520response%2520to%2520immune%2520checkpoint%2520inhibitors%2520in%2520advanced%2520renal%2520cell%2520carcinoma "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.01.26361892v1%26title%3DBaseline%2520intratumoral%2520TCRbeta%253B%2520and%2520TCRgamma%253B%2520repertoires%2520predict%2520respon
## Related Clinical Research

- [miRNA Diagnostic Accuracy for Upper Aerodigestive Tract Malignancies: Systematic Review Protocol](https://medichelpline.com/clinical-feed/bmj-open-7-diagnostic-accuracy-of-mirna-in-detection-of-upper-aerodigestive-tract.md)
- [Uterine Fibroids and Female Sexual Dysfunction: Clinical Impact and Management Considerations](https://medichelpline.com/clinical-feed/pubmed-42700268.md) (DOI: 10.1080/0167482X.2026.2723609)
- [Translational modelling questions receptor‑occupancy‑based dosing for pembrolizumab (PD‑1 inhibito](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-translational-modelling-challenges-receptor-occupancy-based-dosing-of-pd-1.md)
- [Neoadjuvant NAC‑TPF permits radiotherapy avoidance in HPV‑associated oropharyngeal cancer: Phase I](https://medichelpline.com/clinical-feed/british-journal-of-cancer-1-neoadjuvant-triplet-chemotherapy-enables-radiotherapy-avoidance-in-human.md)
- [Explainable Ensemble AI for Melanoma Detection with Leakage-Free Internal Validation](https://medichelpline.com/clinical-feed/medrxiv-0-skin-cancer-classification-using-explainable-artificial-intelligence-with-an.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.